Keyword: Eli Lilly

Eli Lilly VP Robert Brown is making the jump to serve as CEO of the skin disease-focused Brickell Biotech.

Lilly is seeking approval of the 5-HT1F agonist on the strength of late-phase data showing the drug can clear headache pain in two hours.

NextCure will use the series B funds to advance Siglec-15-targeting antibody NC318 and another asset through early-phase clinical development.

Eli Lilly is dropping a BACE inhibitor that was being tested in combination in Alzheimer's disease.

The deal gives Lilly a source of antibodies against novel cancer targets in return for $25 million upfront and undisclosed milestones.

Roche is licensing Halozyme's Enhanze drug delivery platform for three new targets. Halozyme could receive up to $165 million in milestones per target.

Terns Pharmaceuticals has bagged $80 million to bankroll a pipeline of drugs for nonalcoholic steatohepatitis acquired from Eli Lilly.

Fresh off a deal with Alexion last week, Dicerna has started off this week with another deal—this time with Eli Lilly.

Pfizer and Eli Lilly have inched closer to getting their NGF blocker tanezumab to the filing stage as an alternative to opioids for chronic pain.

Merck beefs up digital work with consumer executive; F-star names ex-Immunocore CEO as leader; and Ziopharm’s R&D head joins Spectrum as CMO.